Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 7,756,233 shares of common stock.
- In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 7,756,233 shares of common stock.
- H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.
- The closing of the offering is expected to occur on or about January 31, 2024, subject to the satisfaction of customary closing conditions.
- The gross proceeds from the offering are expected to be approximately $14 million.